Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Scholar Rock Holdings Corporation | SRRK | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 14.09 | 04:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 14.09 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 5.56 - 21.17 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 14.09 | USD |
Scholar Rock Holdings Corporation Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 1.02B | 72.14M | - | 0 | -165.79M | -2.30 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Scholar Rock News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SRRK Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 13.70 | 15.13 | 13.18 | 14.14 | 713,556 | 0.39 | 2.85% |
| 1 Month | 17.19 | 17.90 | 13.11 | 14.94 | 656,588 | -3.10 | -18.03% |
| 3 Months | 14.08 | 17.90 | 12.81 | 15.50 | 818,367 | 0.01 | 0.07% |
| 6 Months | 8.46 | 21.17 | 8.35 | 15.42 | 887,831 | 5.63 | 66.55% |
| 1 Year | 7.27 | 21.17 | 5.56 | 12.80 | 660,944 | 6.82 | 93.81% |
| 3 Years | 35.00 | 44.95 | 4.325 | 12.71 | 483,113 | -20.91 | -59.74% |
| 5 Years | 17.92 | 70.00 | 4.325 | 20.33 | 446,701 | -3.83 | -21.37% |
Scholar Rock Description
| Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company primarily operates in the United States. The company's lead product candidate is SRK-015 which is a highly selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. |
